Iovance Biotherapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $31,106 | $715 | $482 | $469 |
Gross Profit | -5,640 | -11,820 | -13,597 | -3,871 |
EBITDA | -91,050 | -107,815 | -111,542 | -118,361 |
EBIT | -101,914 | -117,722 | -121,256 | -128,236 |
Net Income | -97,101 | -112,976 | -116,379 | -113,760 |
Net Change In Cash | 31,106 | 715 | 482 | 469 |
Free Cash Flow | -98,871 | -126,450 | -87,499 | -87,660 |
Cash | 228,752 | 134,187 | 114,888 | 267,720 |
Basic Shares | 284,817 | 266,220 | 255,951 | 245,817 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,189 | $238 | $0 | $0 |
Gross Profit | -31,938 | -21,135 | -13,980 | -8,712 |
EBITDA | -427,432 | -377,743 | -328,723 | -260,797 |
EBIT | -460,559 | -398,878 | -342,703 | -269,509 |
Net Income | -444,037 | -389,923 | -327,821 | -257,225 |
Net Change In Cash | 1,189 | 238 | 0 | 0 |
Cost of Revenue | 11,459 | 53,435 | ||
Free Cash Flow | -384,110 | -313,182 | -265,515 | -251,925 |
Cash | 114,888 | 231,731 | 78,229 | 67,329 |
Basic Shares | 235,131 | 159,259 | 153,406 | 138,301 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.34 |
2024-03-31 | -$0.42 |
2023-12-31 | -$0.45 |
2023-09-30 | -$0.46 |
